好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Predictors of Processing Speed Test Performance in a Large Multiple Sclerosis Population
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
15-001
To determine the evolution of raw PST scores among patients with MS and to identify PST performance. 

The Performance Speed Test (PST) is an electronic implementation of the symbol digit modalities test. The PST has been longitudinally administered to a multi-institutional multiple sclerosis (MS) population as part of the MS PATHS (Partners Advancing Technology and Health Solutions) initiative.

Data were extracted from the MS PATHS database. Inclusion required a diagnosis of MS and ≥1 PST evaluation. Correlations were determined between numeric predictors and PST scores using Spearman’s Correlation Coefficient. Analysis of variance with planned contrasts was used for categorical variables. Linear regression predicting PST was employed adjusting for important covariates.

We identified 9,004 participants (15,000 unique visits). The mean age was 47 years and the mean disease duration was 11.74 years. Age most strongly correlated with PST performance (r = -0.47, p<0.001) with years from diagnosis also negatively correlating with PST scores (r = -0.33, p<0.001). PST scores positively correlated with education years (r = 0.27, p<0.001). Participants with private insurance had mean PST scores that were 9.9 points higher than those with public insurance (p<0.001). Participants with relapsing-remitting MS (RRMS) had mean scores that were 2 points higher than those with progressive MS (p<0.001) and those with relapsing onset MS had mean scores 1.23 points higher than those with progressive onset MS (p<0.001). The regression model accounted for 43.1% of PST variance and all predictors were significant. PST score decreased by 0.43 points for each year of age (p<0.001). Having primary progressive MS reduced scores by 10.26 points relative to RRMS (p<0.001). A significant interaction revealed that scores dropped at a faster rate per year for those with progressive MS. 

Multiple predictors of PST performance were identified. Age and MS phenotype exerted an especially strong influence.

Authors/Disclosures
Devon Conway, MD
PRESENTER
Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Conway has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Conway has received research support from Novartis. The institution of Dr. Conway has received research support from BMS. The institution of Dr. Conway has received research support from Biogen.
Robert A. Bermel, MD, FAAN (Cleveland Clinic) Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Bermel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Bermel has received research support from Biogen. The institution of Dr. Bermel has received research support from Roche. The institution of Dr. Bermel has received research support from Novartis. Dr. Bermel has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file